Secondary cytoreductive surgery for recurrent mullerian adenocarcinomas: A comparison of serous and non-serous subtypes.

Abstract

e15544 Background: The aim of the study was to evaluate the effects of secondary cytoreductive surgery on survival in patients with recurrent epithelial ovarian, tubal, and peritoneal cancer. Methods: Among all patients who underwent primary therapy for epithelial ovarian, tubal, and peritoneal cancer between 1994 and 2006 at our insitution, the medical records of all patients who were submitted to secondary cytoreductive surgery were retrospectively investigated. Survival analysis was estimated by Kaplan-Meier methods. Results: In total, 34 patients met the inclusion criteria, of whom, 26 had serous, 4 had endometrioid and 4 had clear cell type adenocarcinomas. Median age at treatment for recurrence was 57 years (range 47-76). Following primary surgical and systematic treatment, recurrence was diagnosed after a median treatment free interval of 10 months (range 2-137). Complete cytoreduction was achieved in 24 of the patients (75%). At the end of a median follow-up of 36 months after treatment for recurrence, 12 patients were alive and well, 6 alive with disease and 16 were dead and median post-recurrence survival was 60 months. When compared between histological subtypes, overall post-recurrence survival of serous adenocarcinoma was significantly worse than that of non-serous (p = 0.048). Conclusions: In the present study, the impact of secondary cytoreductive surgery on a significant survival benefit was identified especially for non-serous type. Further analyses are needed to better define the role of surgery in these patients. No significant financial relationships to disclose.